CompletedEUCTR 2014-005206-37
A Double-Blind, Placebo-Controlled, Multicenter Study of Sirukumab as Adjunctive Treatment to a MonoAminergic antidepressant in Adults with Major Depressive Disorder
This historical record does not confirm current site availability.
Historical research recordPoland + United KingdomDepression
Understand this study
What did researchers investigate?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
Who was this study for?
This study was for people with depression. Other eligibility criteria applied.
- Listed locations
- Poland · United Kingdom
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateNot clearly listed
- Recruitment status
- Completed
- Enrollment listed in the registry
- 192
- Sponsor
- Janssen-Cilag International N.V.
- Sponsor type
- Unknown or unclear
- Study type
- Biological
- Intervention type
- BIOLOGICAL
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United Kingdom, Poland
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2014-005206-37
- Official title
Show the full official title
A Double-Blind, Placebo-Controlled, Multicenter Study of Sirukumab as Adjunctive Treatment to a MonoAminergic antidepressant in Adults with Major Depressive Disorder
Recruitment & locations
CompletedPoland · United Kingdom
Registry details
Historical country statuses
- United Kingdom — Completed
- Poland — Completed
Questions about this study
Who is behind this study?
The study sponsor is Janssen-Cilag International N.V.
Who was this study for?
This study was for people with depression. Other eligibility criteria applied.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meRelated studies
Psilocybin vs. escitalopram for major depressive disorder: comparative mechanisms
(GluEsk) Glutamate and Esketamine